As Seagen Matures, CEO Siegall Talks About Moving The Growth Goalposts
Executive Summary
The ADC specialist could have a fourth cancer drug on the market this year and is preparing for its first commercial launch in Europe.
You may also be interested in...
Seagen CEO Search Under Way As Longtime Leader Siegall Resigns In Scandal
Chief medical officer Roger Dansey has stepped in as interim CEO until a new one is appointed.
Seagen/Genmab's Tivdak Set To Take On Merck’s Keytruda
Accelerated approval of Tivdak in recurrent or metastatic cervical cancer brings Seagen’s fourth cancer therapy and third antibody-drug conjugate to market. Merck is advancing Keytruda in r/mCC as well.
Lilly Tops Biopharma Innovation Survey For First Time
Conducting sector survey for a tenth year, Idea Pharma’s Mike Rea said: “COVID-19 showed companies with more agile decision-making were more likely to succeed.”